|
|
BI-Eng2 |
|
Vaxjo ID |
149 |
|
Vaccine Adjuvant Name |
BI-Eng2 |
|
Adjuvant VO ID |
VO_0005507
|
|
Description |
Vaccine adjuvant with CLR(dectin, mincle) that is primarily composed of protein and actives innate immune pathways to induce a mixed Th1/Th2 response |
|
Stage of Development |
Research |
|
Location Licensed |
US (University of Wisconsin) |
|
Host Species for Testing |
Mouse |
|
Second Host Species for Testing |
Rabbit |
|
Components |
glycoprotein |
|
Function |
Type: microbial derivative vaccine adjuvant. Target Receptor: C-type lectin domain family 6 member A (Dectin-2) | C-type lectin domain family 4 member E (Mincle). Induces Th1/Th2 mixed immune profile. induces the production of IL-1β and IL-6 by dendritic cells and acts as an adjuvant to promote differentiation of CD4+ T cells into anti-fungal Th17 cells |
| References |
Dobson et al., 2020: Dobson HE, Dias LDS, Kohn EM, Fites S, Wiesner DL, Dileepan T, Kujoth GC, Abraham A, Ostroff GR, Klein BS, Wüthrich M. Antigen discovery unveils resident memory and migratory cell roles in antifungal resistance. Mucosal immunology. 2020; 13(3); 518-529. [PubMed: 31900406].
VAC-97: Bl-Eng2: [https://vac.niaid.nih.gov/view?id=97]
Wang et al., 2017: Wang H, Lee TJ, Fites SJ, Merkhofer R, Zarnowski R, Brandhorst T, Galles K, Klein B, Wüthrich M. Ligation of Dectin-2 with a novel microbial ligand promotes adjuvant activity for vaccination. PLoS pathogens. 2017; 13(8); e1006568. [PubMed: 28793349].
|
|
